SAB Biotherapeutics’ (SABS) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of SAB Biotherapeutics (NASDAQ:SABS) in a report issued on Tuesday morning, Benzinga reports. HC Wainwright currently has a $6.00 target price on the stock.

Separately, Chardan Capital reissued a buy rating and set a $25.00 target price on shares of SAB Biotherapeutics in a research note on Tuesday.

SAB Biotherapeutics Stock Performance

NASDAQ:SABS opened at $4.41 on Tuesday. SAB Biotherapeutics has a one year low of $4.00 and a one year high of $11.90. The company has a quick ratio of 5.45, a current ratio of 5.45 and a debt-to-equity ratio of 0.06. The stock has a 50 day moving average price of $4.92 and a 200 day moving average price of $3.13.

Institutional Investors Weigh In On SAB Biotherapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in SAB Biotherapeutics by 2.0% during the fourth quarter. Vanguard Group Inc. now owns 996,132 shares of the company’s stock worth $685,000 after acquiring an additional 19,194 shares during the last quarter. BVF Inc. IL acquired a new stake in SAB Biotherapeutics during the fourth quarter worth $6,310,000. Pathstone Holdings LLC acquired a new stake in SAB Biotherapeutics during the fourth quarter worth $348,000. Commodore Capital LP acquired a new stake in SAB Biotherapeutics during the fourth quarter worth $1,259,000. Finally, Kestra Advisory Services LLC boosted its position in shares of SAB Biotherapeutics by 319.0% during the fourth quarter. Kestra Advisory Services LLC now owns 88,000 shares of the company’s stock worth $60,000 after buying an additional 67,000 shares during the period. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.